RxDoctor Payments Data

Carl Snyderman

Otolaryngology · Pittsburgh, PANPI 1104891258

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (45.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Spiway, LLC at 45.6% of the total. Reporting peaked in 2024 at $2,997 and has fallen 91.7% since, to $250 in 2025.

$6,131in general payments, 2019–2025

Across 26 payments — averaging $235.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Spiway, LLC$3K
  • Stryker$2K
  • KARL Storz Endoscopy-america$1K
  • Integra Lifesciences Corporation$239
  • Medtronic$167
$14,987in research payments, 2019–2025

Across 1 payment — averaging $14,987 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bayer Healthcare LLC$15K
$5,194in ownership & investment interests, 2019–2025

Across 2 payments — averaging $2597.00 each. An ownership or investment interest held by the physician or an immediate family member.

  • Spiway, LLC$5K

What the payments were for

  • Consulting fees$2,79446%
  • Travel & lodging$2,06234%
  • Food & beverage$1,27521%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Spiway, LLC1$2,794
Stryker17$1,919
KARL Storz Endoscopy-america4$1,012
Integra Lifesciences Corporation3$239
Medtronic1$167

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,131 in reported general payments places this provider in the 85th percentile of 456 otolaryngology providers in Pennsylvania.

See all otolaryngology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$61,019
Medicare patients
80
Services billed
270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluticasone Propionate112$846
Ipratropium Bromide26$760
Azelastine Hcl20$333
Chlorhexidine Gluconate25$118
Doxycycline Hyclate11$47

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →